Non-alcoholic steatohepatitis in the Asia-Pacific region: Future shock?

Journal of Gastroenterology and Hepatology (Australia)

Volumn 19, Issue 4, 2004, Pages 368-374

  Chitturi, Shivakumar ^a   Farrell, Geoffrey C ^a   George, Jacob ^a,b  

^a UNIVERSITY OF SYDNEY   (Australia)

^b WESTMEAD HOSPITAL   (Australia)

Author keywords

Fatty liver; Hepatic fibrosis; Insulin resistance; Obesity

Indexed keywords

FATTY ACID;

ALCOHOLISM; ASIA; CLINICAL FEATURE; COHORT ANALYSIS; COMPARATIVE STUDY; DEVELOPED COUNTRY; DEVELOPING COUNTRY; DIETARY INTAKE; DISEASE SEVERITY; EPIDEMIC; EPIDEMIOLOGICAL DATA; FUTUROLOGY; HEALTH CARE COST; HEPATITIS; HEPATITIS C; HUMAN; INCIDENCE; LIFESTYLE; LIVER DISEASE; METABOLIC DISORDER; MORBIDITY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONALCOHOLIC FATTY LIVER; OBESITY; PHYSICIAN; POPULATION; PREVALENCE; PRIORITY JOURNAL; PROPHYLAXIS; REVIEW; RISK FACTOR;

EID: 2342459634     PISSN: 08159319     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1440-1746.2003.03252.x     Document Type: Review

References (64)

1. Caldwell SH, Oelsner DH, Iezzoni JC et al. Cryptogenic cirrhosis: clinical characterization and risk factors for underlying disease. Hepatology 1999; 29: 664-9.
2. Ludwig J, Viggiano TR, McGill DB, Oh BJ. Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin. Proc. 1980; 55: 434-8.
3. Chitturi S, Farrell GC. Etiopathogenesis of nonalcoholic steatohepatitis. Semin. Liver Dis. 2001; 21: 27-41.
4. Reid AE. Nonalcoholic steatohepatitis. Gastroenterology 2001; 121: 710-23.
5. Angulo P. Nonalcoholic fatty liver disease. N. Engl. J. Med. 2002; 16: 1221-31.
6. Tilg H, Diehl AM. Cytokines in alcoholic and nonalcoholic steatohepatitis. N. Engl. J. Med. 2000; 343: 1467-76.
7. Itoh S, Igarashi M, Tsukada Y et al. Nonalcoholic fatty liver with alcoholic hyaline after long-term glucocorticoid therapy. Acta Hepatogastroenterol. 1977; 24: 415-18.
8. Oshibuchi M, Nishi F, Sato M et al. Frequency of abnormalities detected by abdominal ultrasound among Japanese adults. J. Gastroenterol. Hepatol. 1991; 6: 165-8.
9. Hasan I, Gani RA, Machmud R et al. Prevalence and risk factors for nonalcoholic fatty liver in Indonesia. J. Gastroenterol. Hepatol. 2002; 17 (Suppl.): A30.
10. Omagari KH, Kadokawa Y, Masuda J et al. Fatty liver in non-alcoholic non-overweight Japanese adults: incidence and clinical characteristics. J. Gastroenterol. Hepatol. 2002; 17: 1089-105.
11. Dixon JB, Bhathal PS, O'Brien PE. Nonalcoholic fatty liver disease: predictors of nonalcoholic steatohepatitis and liver fibrosis in the severely obese. Gastroenterology 2001; 121: 91-100.
12. Powell EE, Cooksley WGE, Hansen R, Searle J, Halliday JW, Powell LW. The natural history of nonalcoholic steatohepatitis. a follow-up study of 42 patients for up to 21 years. Hepatology 1990; 11: 74-80.
13. Chitturi S, Abeygunasekera S, Farrell GC et al. NASH and insulin resistance: insulin hypersecretion and specific association with the insulin resistance syndrome. Hepatology 2002; 35: 373-8.
14. Chitturi S, Farrell G, Frost L et al. Serum leptin in NASH correlates with hepatic steatosis but not fibrosis: a manifestation of lipotoxicity? Hepatology 2002; 36: 403-9.
15. Tobe K, Ogura T, Tsukamoto C et al. Relationship between serum leptin and fatty liver in Japanese male adolescent university students. Am. J. Gastroenterol. 1999; 94: 3328-35.
16. George DK, Goldwurm S, MacDonald GA et al. Increased hepatic iron concentration in nonalcoholic steatohepatitis is associated with increased fibrosis. Gastroenterology 1998; 114: 311-18.
17. Chitturi C, Weltman M, Farrell GC et al. HFE mutations, hepatic iron, and fibrosis: ethnic-specific associations of NASH with C282Y but not with fibrotic severity. Hepatology 2002; 36: 142-8.
18. Weltman MD, Farrell GC, Ingelman-Sundberg M, Liddle C. Hepatic cytochrome P450 2E1 is increased in patients with nonalcoholic steatohepatitis. Hepatology 1998; 27: 128-33.
19. Weltman MD, Farrell GC, Liddle C. Increased hepatocyte CYP2E1 expression in a rat nutritional model of hepatic steatosis with inflammation. Gastroenterology 1996; 111: 1645-53.
20. Leclercq IA, Farrell GC, Field J, Robertson GR. Cyp2E1 and CYP4A as microsomal catalysts of lipid peroxides in murine non-alcoholic steatohepatitis. J. Clin. Invest. 2000; 105: 1067-75.
21. Seki K, Minami Y, Nishikawa M et al. Nonalcoholic steatohepatitis induced by massive doses of synthetic estrogen. Gastroenterol. Jpn. 1983; 18: 297-303.
22. Ogawa Y, Murata Y, Nishioka A, Inomata T, Yoshida S. Tamoxifen-induced fatty liver in patients with breast cancer (Letter). Lancet 1998; 351: 725.
23. Powell EE, Searle J, Mortimer R. Steatohepatitis associated with limb lipodystrophy. Gastroenterology 1989; 97: 1022-4.
24. Ueno T, Sugawara H, Sujaku K et al. Therapeutic effects of restricted diet and exercise in obese patients with fatty liver. J. Hepatol. 1997; 27: 103-7.
25. Younossi ZM, Diehl AM, Ong JP. Nonalcoholic fatty liver disease: an agenda for clinical research. Hepatology 2002; 35: 746-52.
26. Manton ND, Lipsett J, Moore DJ et al. Non-alcoholic steatohepatitis in children and adolescents. Med. J. Aust. 2000; 173: 476-9.
27. Poonawala A, Nair SP, Thuluvath PJ. Prevalence of obesity and diabetes in patients with cryptogenic cirrhosis: a case study. Hepatology 2000; 32: 689-92.
28. Lee RG. Nonalcoholic steatohepatitis: a study of 49 patients. Hum. Pathol 1989; 20: 594-8.
29. Matteoni CA, Younossi ZM, Gramlich T, Boparai N, Liu YC, McCullough AJ. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology 1999; 116: 1413-19.
30. Ratziu V, Bonyhay L, Di Martino V et al. Survival, liver failure and hepatocellular carcinoma in obesity-related cirrhosis. Hepatology 2002; 35: 1485-93.
31. Shimada M, Hashimoto E, Taniai M et al. Hepatocellular carcinoma in patients with non-alcoholic steatohepatitis. J. Hepatol. 2002; 37: 154-60.
32. Angulo P, Keach JC, Batts KP, Lindor KD. Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis. Hepatology 1999; 30: 1356-62.
33. Zimmet P, Alberti KG, Shaw J. Global and societal implications of the diabetes epidemic. Nature 2001; 414: 782-7.
34. Dunstan DW, Zimmet PZ, Welborn TA et al. The Australian Diabetes, Obesity and Lifestyle Study (AusDiab): methods and response rates. Diabetes Res. Clin. Pract. 2002; 57: 119-29.
35. Magarey AM, Daniels LA, Boulton TJ. Prevalence of overweight and obesity in Australian children and adolescents: reassessment of 1985 and 1995 data against new standard international definitions. Med. J. Aust. 2001; 174: 561-4.
36. Baldridge AD, Perez-Atayde AR, Graeme-Cook F, Higgins L, Lavine JE. Idiopathic steatohepatitis in childhood: a multicenter retrospective study. J. Pediatr. 1995; 127: 700-4.
37. Rashid M, Roberts E. Nonalcoholic steatohepatitis in children. J. Pediatr. Gastroenterol. Nutr. 2000; 30: 48-53.
38. Samarasinghe D, Tasman-Jones C. The clinical associations with hepatic steatosis: a retrospective study. N.Z. Med. J. 1992; 105: 57-8.
39. Leung NWY, Tsang TWC, Liew CT, Tomlinson B. Nonalcoholic steatohepatitis (NASH) in Hong Kong-role of hepatologist in the diagnosis of diabetes mellitus (Abstract). In: Abstracts of World Congress of Gastroenterology, Vienna, 1998. Basel: Karger, 1998.
40. Agarwal SR, Malhotra V, Sakhuja P, Sarin SK. Clinical, biochemical and histological profile of nonalcoholic steatohepatitis. Indian J. Gastroenterol. 2001; 20: 183-6.
41. Amarapurkar DN, Amarapurkar AD. Nonalcoholic steatohepatitis: clinicopathological profile. J. Assoc. Physicians India 2000; 48: 311-13.
42. Park J, Kim MK, Kim SJ et al. Clinical predictors reflecting the pathologic grade of nonalcoholic steatohepatitis in patients with nonalcoholic fatty liver: Korean cases different from western patients (Abstract). Hepatology 2000; 32: 419A.
43. Janaki S, Hewavisenthi S. Profile of non-alcoholic steatohepatitis in a Sri Lankan population (Abstract). J. Gastroenterol. Hepatol. 2001; 16 (Suppl.): A81.
44. Whincup PH, Gilg JA, Papacosta O et al. Early evidence of ethnic differences in cardiovascular risk: cross sectional comparison of British South Asian and white children. BMJ 2002; 324: 635.
45. Bacon BR, Farakvash MJ, Janney CG et al. Nonalcoholic steatohepatitis: an expanded clinical entity. Gastroenterology 1994; 107: 1103-9.
46. Hui JM, Chitturi S, Farrell GC, George J. The long-term outcome of cirrhosis related to non-alcoholic steatohepatitis. J. Gastroenterol. Hepatol. 2002; 17 (Suppl.): A154.
47. Palmer M, Schaffner F. Effect of weight reduction on hepatic abnormalities in overweight patients. Gastroenterology 1990; 99: 1408-13.
48. Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N. Engl. J. Med. 2002; 346: 393-403.
49. Tuomilehto J, Lindstrom J, Eriksson JG et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N. Engl. J. Med. 2001; 344: 1343-50.
50. Toh MC, Cutter J, Chew SK. School based intervention has reduced obesity in Singapore (Letter). BMJ. 2002; 324: 427.
51. Angulo P, Lindor KD. Treatment of nonalcoholic fatty liver: present and emerging therapies. Semin. Liver Dis. 2001; 21: 81-8.
52. Hasegawa T, Yoneda M, Nakamura K, Makino I, Terano A. Plasma transforming growth factor-beta1 level and efficacy of alpha-tocopherol in patients with non-alcoholic steatohepatitis: a pilot study. Aliment. Pharmacol. Ther. 2001; 15: 1667-72.
53. International Diabetes Institute. The Asia-Pacific Perspective: Redefining Obesity and its Treatment. Sydney: Health Communications Australia, 2000.
54. Meek SE, Nair KS, Jensen MD. Insulin regulation of regional free fatty acid metabolism. Diabetes 1999; 48: 10-14.
55. Thomas GN, Tomlinson B, Critchley JAJH. Guidelines for healthy weight (Letter). N. Engl. J. Med. 1999; 341: 2097-8.
56. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 2002; 25: S5-S20.
57. Avignon A, Boegner C, Mariano-Goulart D, Colette C, Monnier L. Assessment of insulin sensitivity from plasma insulin and glucose in the fasting or post oral glucose-load state. Int. J. Obes. Relat. Metab. Disord. 1999; 23: 512-17.
58. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28: 412-19.
59. Akahoshi M, Amasaki Y, Soda M et al. Correlation between fatty liver and coronary risk factors: a population study of elderly men and women in Nagasaki, Japan. Hypertens. Res. 2001; 24: 337-43.
60. Clark JM, Brancati FL, Diehl AM. Nonalcoholic fatty liver disease. Gastroenterology 2002; 122: 1649-57.
61. Valenti L, Fracanzani AL, Dongiovanni P et al. Tumor necrosis factor alpha promoter polymorphisms and insulin resistance in nonalcoholic fatty liver disease. Gastroenterology 2002; 122: 274-80.
62. Crespo J, Cayon A, Fernandez-Gil P et al. Gene expression of tumor necrosis factor alpha and TNF-receptors, p55 and p75, in nonalcoholic steatohepatitis patients. Hepatology 2001; 34: 1158-63.
63. Iwamoto N, Ogawa Y, Kajihara S et al. Gln27Glu beta2-adrenergic receptor variant is associated with hypertriglyceridemia and the development of fatty liver. Clin. Chim. Acta 2001; 314: 85-91.
64. Hourigan LF, Macdonald GA, Purdie D et al. Fibrosis in chronic hepatitis C correlates with body mass index and steatosis. Hepatology 1999; 29: 1215-19.